Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | A66 |
Synonyms | |
Therapy Description |
A66 inhibits PIK3CA, preventing the activation of the PI3K signaling pathway and potentially inhibiting tumor cell proliferation (PMID: 21668414, PMID: 28360038). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
A66 | PIK3CA inhibitor 24 | A66 inhibits PIK3CA, preventing the activation of the PI3K signaling pathway and potentially inhibiting tumor cell proliferation (PMID: 21668414, PMID: 28360038). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA H1047R | Advanced Solid Tumor | sensitive | A66 | Preclinical | Actionable | In a preclinical study, A66 delayed tumor growth in human tumor xenograft models harboring PIK3CA H1047R mutations (PMID: 21668414). | 21668414 |
PTEN mutant | endometrial cancer | resistant | A66 | Preclinical | Actionable | In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to A66 induced growth inhibition in culture (PMID: 23674493). | 23674493 |
BRAF V600E/K PIK3CA wild-type | melanoma | no benefit | A66 | Preclinical | Actionable | In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449). | 26137449 |
PTEN loss | glioblastoma | resistant | A66 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, A66 did not inhibit tumor growth in a PTEN-null cell line xenograft model of glioblastoma (PMID: 21668414). | 21668414 |
PIK3CA E545K | Advanced Solid Tumor | resistant | A66 | Preclinical | Actionable | In a preclinical study, cancer cell lines harboring PIK3CA E545K did not demonstrate sensitivity to A66 in culture, in contrast with cells harboring PIK3CA H1047R (PMID: 21668414). | 21668414 |
PIK3CA H1047R | ovarian cancer | sensitive | A66 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, A66 delayed tumor growth in an ovarian cancer cell line xenograft model harboring PIK3CA H1047R (PMID: 21668414). | 21668414 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|